Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course OSHA Bloodborne Pathogens. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about OSHA Bloodborne Pathogens (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 111 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Histology CE Package$65 Add to cart
Phlebotomy CE Package$45 Add to cart
Individual course$20 Add to cart

Recent Information Regarding HCV Infection and Treatment

According to the CDC, persons born between 1945-1965 account for three-fourths of the cases of HCV infection. This group is also at greatest risk for hepatocellular carcinoma and other HCV-related liver diseases. The CDC recommends a one-time HCV testing for all persons born between 1945-1965.
Although there is still no vaccine for HCV, there are now several treatment options available. In October 2014, the FDA approved a once-daily tablet treatment for chronic HCV genotype 1, the most common form of HCV in the United States. This treatment has proven cure rates of 94-99%. An infected individual is considered cured, if the virus is not detected in the blood 12 weeks after completion of treatment. Since then, several other treatments have been approved, including one that is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection.